Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima ...Middle East

PR Newswire - News
STOCKHOLM, June 2, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that a safe dose has been established for treatment with the drug candidate...

Hence then, the article about medivir has completed the dose escalation part phase 1b of the 1b 2a study in hcc and focuses on the combination of fostrox and lenvima was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News